ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Airlangga University Professor develops New Epilepsy Treatment



Surabaya, East Java, Indonesia, Oct 30, 2023 - (ACN Newswire) - A medical professor at Airlangga University, Prastiya Indra Gunawan, has developed a new epilepsy treatment method that involves administering midazolam intramuscularly and intranasally.

Airlangga University professor Prastiya Indra Gunawan has devised a new treatment method that involves providing midazolam intramuscularly and intranasally to epilepsy patients.
Airlangga University professor Prastiya Indra Gunawan has devised a new treatment method for epilepsy patients that involves providing midazolam intramuscularly and intranasally. [Image: Airlannga]

The new method can be a solution for treating epilepsy, for which electroencephalography (EGG) examinations have been used so far. The results of those examinations are often misinterpreted, causing excessive diagnosis of epilepsy and prolonged use of antiepileptic drugs, which is not necessary.

"Intramuscular midazolam is able to stop seizures within 45 seconds, while intranasal midazolam is able to stop seizures within 42 seconds. This is different from rectal diazepam, which takes 180 seconds," Professor Gunawan, a pediatrician from Airlangga University, said.

He has received recognition as a pioneer in changing the procedures for handling childhood seizures and has obtained intellectual property rights (IPR). Gunawan officially obtained the IPR in 2019 and 2021 based on the research and publications he carried out in 2015 and 2016.

Gunawan has made other advances in the field, having diagnosed epilepsy in patients who were drug resistant and had been diagnosed with other causes.

"In terms of diagnostics, the diagnosed cause was infection, the diagnosed cause was head trauma, but now, we are also developing diagnosis to include autoimmune. Indeed, we have been able to diagnose patients who have epilepsy with a resistance to drugs. We continued to look for it, and the cause is autoimmune," he said.

Even after the cause has been identified, seizures that are resistant to adequate medication are still difficult to treat. In this case, according to Gunawan, surgery can be an alternative.

Unfortunately, not all health facilities can perform epilepsy surgery. With the current technological advances, Gunawan said it is necessary to build a comprehensive epilepsy service center, an idea which he shared at the N-20 Conference during the G20 Summit in Bali in 2022.

"The key to this epilepsy center is to assemble the right team with the right people who have the same approach to dealing with epilepsy," he said. "The epilepsy center will not only be for treatment but will help address social stigma. Many people with epilepsy feel isolated by their environment, hampered in their careers, and feel they have failed in their home life."

With the establishment of the epilepsy center, Gunawan said he hopes that people with epilepsy will not only receive healthcare, but also see improvements in their social life. He also invited everyone to work together to care for epilepsy sufferers.

Reporter: Yashinta Difa Pramudyani
Editor: Tia Mutiasari
Copyright (c) ANTARA 2023

]]>

Source: Airlangga University

Copyright 2023 ACN Newswire . All rights reserved.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.